Cas No.: | 114-07-8 |
Chemical Name: | (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione |
Synonyms: | Erythromycin A, E-Mycin, Abomacetin, Erymax, erythro, Erythromycinum, Ilotycin, Emgel, 114-07-8 |
SMILES: | C[C@@H]([C@@H]([C@@H](C)C(O[C@H](CC)[C@@](C)(O)[C@H](O)[C@H]1C)=O)O[C@H]2C[C@](OC)(C)[C@@H](O)[C@H](C)O2)[C@H]([C@](C)(O)C[C@@H](C)C1=O)O[C@H]3[C@H](O)[C@@H](N(C)C)C[C@@H](C)O3 |
Formula: | C37H67NO13 |
M.Wt: | 733.93 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used For people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and Legionellosis. In a study of in-vitro and in-vivo susceptibility of Borrelia burgdorferito, erythromycin possessed low activity, having an ED50 of 122.2 (±51.9) mg/kg. For erythromycin, an IC50 of 1.5 μg/ml was observed, indicating a fourfold lower sensitivity of the organisms to this compound. For the detailed information of E-Mycin, the solubility of E-Mycin in water, the solubility of E-Mycin in DMSO, the solubility of E-Mycin in PBS buffer, the animal experiment (test) of E-Mycin, the cell expriment (test) of E-Mycin, the in vivo, in vitro and clinical trial test of E-Mycin, the EC50, IC50,and Affinity of E-Mycin, Please contact DC Chemicals. |